Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Phico Therapeutics
Phico Therapeutics
Activities:
Research & Development
Infection Control
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
TerraCycle launches BlisterBack solution to increase medicine blister pack recycling
The initiative allows the collection and recycling of medicine blister packs, which would otherwise end up in landfill
UPS Healthcare supports Irish pharma with novel Dublin facility
The opening of the facility will expand the global connectivity of the Irish pharmaceutical market, which accounts for 50% of all national exports
Oxford BioDynamics and King’s College London collaborate to develop EpiSwitch biomarkers for rheumatoid arthritis
Prognostic and predictive biomarkers determined by EpiSwitch technology will allow for best prevention of rheumatoid arthritis following the APIPPRA trial
TekniPlex Healthcare at ACHEMA: the company presents automatic filler-sealer for single dose plastic vials
The company will exhibit a range of blister packaging solutions, as well as its latest filling and sealing machine model at ACHEMA 2024
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all
Related Content
Phico Therapeutics appoints Financial Director and two non-executives
Pharmaceutical
Phico Therapeutics awarded Innovate UK funding
The funding will support development of a <i>Pseudomonas aeruginosa</i> targeted therapeutic, to tackle the genetic cause of antibiotic resistance
Research & Development
Phico Therapeutics receives £2.25m grant to advance its SASPject PT4 towards clinical trials
The antibiotic is aimed at Escherichia coli and Klebsiella pneumoniae
Research & Development
Phico raises further funds to fight E.coli
To develop SASPject antibiotic technology
Research & Development
Phico Therapeutics raises £1.8m to advance new class of antibiotics
Technology could form the basis of a new class of antibiotics
Subscribe now